Castration-Resistant Prostate Carcinoma Clinical Trials
3 recruiting trials for Castration-Resistant Prostate Carcinoma. Eligibility criteria explained in plain English.
TrialFinderData lists 3 Castration-Resistant Prostate Carcinoma clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Across the trials that carry a phase, Phase 1 / Phase 2 is the largest group at 50% (1 studies); the largest phase groups are Phase 1 / Phase 2: 1, Phase 1: 1.
Research is led by University of Michigan Rogel Cancer Center (1), M.D. Anderson Cancer Center (1), Roswell Park Cancer Institute (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is Biopsy (procedure, 2 trials), followed by Bone Scan, Computed Tomography.
Track Castration-Resistant Prostate Carcinoma trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
This phase I/II tests the safety, side effects and best dose of ruxolitinib in combination with enzalutamide and how well it works in treating patients with prostate cancer that...
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME...
This trial compares cryoablation combined with stereotactic body radiation therapy to stereotactic body radiation therapy alone to see how well they work in treating patients with...
Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration...
This phase I trial tests the change in androgen receptor sensitivity, side effects and effectiveness of bipolar androgen therapy, using testosterone, in patients with castration...
Explore Other Conditions
Frequently Asked Questions
There are currently 3 clinical trials for Castration-Resistant Prostate Carcinoma, with 3 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Castration-Resistant Prostate Carcinoma, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Castration-Resistant Prostate Carcinoma, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.